End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
84,000 KRW | -0.24% | +0.48% | -16.33% |
Jan. 30 | SK Biopharmaceuticals Swings to Profit in Q4 | MT |
2023 | SK Group Advances Net Zero Transition via Key Renewable Energy Deal | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With an expected P/E ratio at 205.82 and 50.3 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.33% | 4.78B | A- | ||
+12.05% | 9.18B | A- | ||
+6.40% | 3.87B | B- | ||
+26.98% | 3.73B | - | ||
+28.27% | 2.52B | B | ||
-26.55% | 2.27B | - | ||
-25.02% | 2.21B | C- | ||
+5.82% | 1.95B | - | - | |
-0.50% | 1.64B | - | - | |
+3.49% | 1.63B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A326030 Stock
- Ratings SK Biopharmaceuticals Co., Ltd.